- Conditions
- Prostatic Neoplasms, Castration-Resistant
- Interventions
- JNJ-809, Apalutamide
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 33
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Prostate Cancer
- Interventions
- Leuprolide acetate, Apalutamide, Radical prostatectomy
- Drug · Procedure
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Prostate Cancer
- Interventions
- EPI-7386 (QD), EPI-7386 (BID), Abiraterone acetate, Apalutamide
- Drug
- Lead sponsor
- ESSA Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 7
- States / cities
- Port Saint Lucie, Florida • Atlanta, Georgia • Boston, Massachusetts + 4 more
- Conditions
- Prostatic Neoplasms
- Interventions
- Apalutamide, Placebo
- Drug
- Lead sponsor
- Aragon Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 122
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Chandler, Arizona + 119 more
- Conditions
- Prostatic Neoplasms
- Interventions
- Apalutamide, Bicalutamide, Bicalutamide Placebo, Apalutamide Placebo, GnRH (agonist), 74-80 Grays (units of radiation)
- Drug · Radiation
- Lead sponsor
- Aragon Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,503 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2028
- U.S. locations
- 60
- States / cities
- Homewood, Alabama • Chandler, Arizona • Scottsdale, Arizona + 57 more
- Conditions
- Healthy
- Interventions
- JNJ-56021927 capsule, JNJ-56021927 tablet
- Drug
- Lead sponsor
- Aragon Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Prostate Cancer
- Interventions
- Apalutamide, Leuprolide, Prednisone, Abiraterone Acetate
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 4
- States / cities
- La Jolla, California • Boston, Massachusetts • New York, New York
- Conditions
- Castration-resistant Prostate Cancer
- Interventions
- Apalutamide, Carotuximab
- Drug
- Lead sponsor
- Edwin Posadas, MD
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- Duarte, California • Los Angeles, California • Salt Lake City, Utah
- Conditions
- Prostatic Neoplasms
- Interventions
- Radiotherapy, LHRHa, Apalutamide
- Radiation · Drug
- Lead sponsor
- Janssen Pharmaceutica N.V., Belgium
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 691 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2031
- U.S. locations
- 13
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Lakewood, Colorado + 10 more
- Conditions
- Prostate Cancer
- Interventions
- ARN-509 (Phase 1), ARN-509 (Phase 2)
- Drug
- Lead sponsor
- Aragon Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2025
- U.S. locations
- 15
- States / cities
- San Diego, California • San Francisco, California • Atlanta, Georgia + 12 more
- Conditions
- Prostate Cancer (Adenocarcinoma)
- Interventions
- Brachytherapy
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 40 Years and older · Male only
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Prostate Cancer
- Interventions
- apalutamide, Everolimus
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Prostate Cancer Metastatic
- Interventions
- Apalutamide, Abiraterone acetate, Docetaxel, Prednisone
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 2
- States / cities
- Omaha, Nebraska • New York, New York
- Conditions
- Prostate Cancer
- Interventions
- Apalutamide, LHRH Analogue, Abiraterone Acetate, Prednisone
- Drug
- Lead sponsor
- Alliance Foundation Trials, LLC.
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 504 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 69
- States / cities
- Phoenix, Arizona • Chula Vista, California • Duarte, California + 58 more
- Conditions
- Prostate Cancer, Metastatic Prostate Cancer
- Interventions
- Abiraterone, Enzalutamide, Apalutamide, Sipuleucel-T
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Columbus, Ohio
- Conditions
- Prostate Cancer
- Interventions
- ARN-509, Abiraterone acetate, Prednisone
- Drug
- Lead sponsor
- Aragon Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Prostate Cancer
- Interventions
- Apalutamide, Placebo, Androgen Deprivation Therapy (ADT)
- Drug
- Lead sponsor
- Aragon Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,052 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 39
- States / cities
- Homewood, Alabama • Tucson, Arizona • San Bernardino, California + 36 more
- Conditions
- Small Cell Neuroendocrine Carcinoma, Prostate Cancer, Small Cell Carcinoma
- Interventions
- Apalutamide, Cetrelimab
- Drug · Biological
- Lead sponsor
- Rahul Aggarwal
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Prostatic Neoplasms
- Interventions
- Apalutamide, ADT, Relugolix
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 32
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Sherman Oaks, California + 28 more
- Conditions
- Metastatic Cancer, Neoplasm, Prostate, Castrate-sensitive, Castrate-sensitive Prostate Cancer
- Interventions
- Abiraterone acetate, Apalutamide, Enzalutamide
- Drug
- Lead sponsor
- Sun Pharmaceutical Industries Limited
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Tampa, Florida • Ann Arbor, Michigan + 9 more
- Conditions
- Prostate Cancer
- Interventions
- ARN-509, Abiraterone Acetate, Prednisone
- Drug
- Lead sponsor
- Daniel George, MD
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 14
- States / cities
- New Orleans, Louisiana • Baltimore, Maryland • Detroit, Michigan + 11 more
- Conditions
- Prostate Cancer
- Interventions
- ARN-509, LHRH Agonist
- Drug
- Lead sponsor
- Aragon Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • San Francisco, California • Chicago, Illinois + 2 more
- Conditions
- Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer
- Interventions
- Relugolix, Abiraterone, Prednisone, Methylprednisolone, Apalutamide, Docetaxel
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 16
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Lakewood, Colorado + 13 more
- Conditions
- Prostatic Neoplasms
- Interventions
- Niraparib, Apalutamide, Abiraterone Acetate, Prednisone
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 4
- States / cities
- West Hollywood, California • Louisville, Kentucky • Portland, Oregon + 1 more